Of the three types of MS, PPMS is considered the rarest, affecting 10% of people living with MS. As with other forms of MS, ...

The cost-effectiveness body had initially said that Ocrevus (ocrelizumab) was too expensive in primary progressive multiple sclerosis (PPMS) in first draft guidance issued last summer. In that ...

Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...

PPMS typically includes a steady loss of function from the onset of symptoms. The vast majority of people with MS receive an ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

A new study, commissioned by the Multiple Sclerosis Society of New Zealand (MSNZ), analysed the cost-effectiveness of Ocrelizumab - which got funded as a treatment for primary progressive multiple ...

Anyone interested in using the instrument should contact Professor Clement Burns. For new materials or new users, we are often able to run a short test measurement without charge to determine whether ...